|
|
• |
|
• |
|
• |
|
• |
|
• |
|
• |
|
• |
 |
|
| • |
|
|
|
|
HIV and AIDS Malignancy Branch
|
|
 |
|
|
Richard F. Little, M.P.H., M.D.
|
| Principal Investigator |
|
Building 10
Room 10S255
10 Center Drive MSC 1868
Bethesda, MD 20892-1868 |
|
|
Phone:
|
(301)402-6296 |
|
Fax:
|
301-480-5955 |
|
E-Mail:
|
RLITTLE@HELIX.NIH.GOV |
|
|
|
| Dr. Richard Little received his B.S. from Tulane University and his M.P.H. and M.D. from the University of South Carolina. He completed his clinical training in internal medicine at the Boston City Hospital and in hematology and oncology in the Hematology Branch, National Heart, Lung, and Blood Institute, and the Medicine Branch of the NCI. He then joined the Laboratory of Tumor Cell Biology where he worked on retroviral strategies for gene transfer. Currently he is a senior oncologist in the Retroviral Diseases Section of the HIV and AIDS Malignancy Branch, which he joined in 1996. |
|
|
Research
|
Clinical Research in HIV Infection and AIDS-Associated Malignancies
Dr. Little’s research has focused on clinical investigations in AIDS-related malignancies, developing treatment strategies for resistant HIV and treatment vaccines for HIV infection.
Recent clinical investigation has focused on developing novel treatment strategies for AIDS-related lymphoma and Kaposi's sarcoma.
Recent work has included the demonstration that dose-adjusted EPOCH chemotherapy is highly effective in AIDS-related lymphoma, yielding responses and disease-free survival equivalent to that in non-AIDS lymphomas of similar histopathology receiving similar treatment. Investigations are now being initiated into lymphoid neoplasms such as multicentric Castleman's disease and primary effusion lymphoma. Both of these tumors are caused by the Kaposi's sarcoma associated herpes virus, and the investigations will be directed toward therapeutic exploitation of the presence of this virus.
Work in Kaposi’s sarcomas focused on treatment approaches that are directed against tumor blood supply. In collaboration with other members of his branch, Dr. Little’s clinical investigations have also focused on novel treatments using these approaches for this tumor.
Collaborating with us are Jay Bersofsky, Giovanna Tosato, Steven Zeichner, Andrea Abati, Stefania Pittaluga, Elaine Jaffe, and Robert Yarchoan, NIH.
|
| |
| This page was last updated on 5/21/2004. |
